Article: Pharma Analysis & QC – Analytix Reporter special edition
Posted: 20 April 2020 | Merck | No comments yet
Biologics continue to be a major modality in the pharmaceutical pipeline. New and unique LC-MS tools will become available for use from discovery through QC.
Some of the characterization of biologics being performed in the LC-MS lab include intact mass, glycan analysis, peptide mapping, impurity and degradant identity, as well as bioanalytical assays for DMPK purposes. Beyond the capabilities of the mass spectrometer, consumables suppliers are now introducing novel sample preparation tools together with isotopically labeled and certified reference standards for the biologics market.
Subscribe here to receive your copy of Analytix Reporter
Download your PDF copy of Analytix Reporter
Related content from this organisation
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Labelling, Manufacturing, Packaging, QA/QC, Regulation & Legislation, Research & Development (R&D)